TY - JOUR
T1 - Manganese Transport Disorder: Novel SLC30A10 Mutations and Early Phenotypes
AU - Quadri, Marialuisa
AU - Kamate, M
AU - Sharma, S
AU - Olgiati, Simone
AU - Graafland, Josja
AU - Breedveld, Guido
AU - Kori, I
AU - Hattiholi, V
AU - Jain, P
AU - Aneja, S
AU - Kumar, A
AU - Gulati, P
AU - Goel, M
AU - Talukdar, B
AU - Bonifati, Vincenzo
PY - 2015
Y1 - 2015
N2 - Background: SLC30A10 mutations cause an autosornal recessive disorder, characterized by hyperrnanganesaennia, polycythennia, early-onset dystonia, paraparesis, or late-onset parkinsonism, and chronic liver disease. This is the first identified inborn error of Mn metabolism in humans, reported in 10 families thus far. Methods: Methods for this study consisted of clinical examination, neuroimaging studies (MRI), serum dosages, and SLC30A10 genetic analysis. Results: We describe early disease manifestations (including videos) in 5 previously unreported Indian children, carrying novel homozygous SLC30A10 mutations. Gait and speech disturbances, falls, dystonias, and central hypotonia were the presenting neurological features, starting within the first 5 years of life. All children also had severe hypermanganesemia, polycythennia, variable degree of liver disease, and marked brain MRI Ti hyperintensities. Conclusions: Our findings expand the mutational and clinical spectra of this recently recognized disorder. An early diagnosis is warranted, because treatment with manganese-chelating agents, iron supplementation, or their combination might improve symptoms and prevent progression of this otherwise potentially fatal disease. (C) 2015 International Parkinson and Movement Disorder Society
AB - Background: SLC30A10 mutations cause an autosornal recessive disorder, characterized by hyperrnanganesaennia, polycythennia, early-onset dystonia, paraparesis, or late-onset parkinsonism, and chronic liver disease. This is the first identified inborn error of Mn metabolism in humans, reported in 10 families thus far. Methods: Methods for this study consisted of clinical examination, neuroimaging studies (MRI), serum dosages, and SLC30A10 genetic analysis. Results: We describe early disease manifestations (including videos) in 5 previously unreported Indian children, carrying novel homozygous SLC30A10 mutations. Gait and speech disturbances, falls, dystonias, and central hypotonia were the presenting neurological features, starting within the first 5 years of life. All children also had severe hypermanganesemia, polycythennia, variable degree of liver disease, and marked brain MRI Ti hyperintensities. Conclusions: Our findings expand the mutational and clinical spectra of this recently recognized disorder. An early diagnosis is warranted, because treatment with manganese-chelating agents, iron supplementation, or their combination might improve symptoms and prevent progression of this otherwise potentially fatal disease. (C) 2015 International Parkinson and Movement Disorder Society
U2 - 10.1002/mds.26202
DO - 10.1002/mds.26202
M3 - Article
C2 - 25778823
SN - 0885-3185
VL - 30
SP - 996
EP - 1001
JO - Movement Disorders
JF - Movement Disorders
IS - 7
ER -